Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.

Bocchia, Monica

Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. [electronic resource] - Oncotarget Nov 2016 - 72311-72321 p. digital

Publication Type: Comparative Study; Journal Article

1949-2553

10.18632/oncotarget.11100 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Agents--therapeutic use
Atherosclerosis--blood
Cross-Sectional Studies
Cytokines--blood
Dyslipidemias--blood
Female
Genetic Predisposition to Disease
Humans
Imatinib Mesylate--therapeutic use
Incidence
Inflammation--chemically induced
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Male
Middle Aged
Oxidation-Reduction--drug effects
Polymorphism, Single Nucleotide
Prospective Studies
Protein Kinase Inhibitors--therapeutic use
Pyrimidines--therapeutic use
Retrospective Studies
Risk Factors
Scavenger Receptors, Class E--genetics
Thrombosis--blood